Karenitecin (Ovarian Cancer) Analysis and Forecast to 2020
Publisher Name » GlobalData
Published Date » 2011-10-20
No. Of Pages » 35
GlobalDatas pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Karenitecin sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.
Scope
- Therapy area profile including patient population for the US, EU and Japan (seven major markets)
- Analysis and review of Karenitecin including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Karenitecin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2014-2020 for Karenitecin in the seven major markets
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drugs performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 8
3 Ovarian Cancer: Market Characterization 9
3.1 Ovarian Cancer Market 9
3.2 Ovarian Cancer Market Forecasts and CAGR 9
3.3 Drivers for Ovarian Cancer Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 12
3.3.4 Emergence of Targeted Drugs 12
3.3.5 Recurrence of Tumor 12
3.3.6 Low Initial Diagnosis Rate 12
4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 13
5 Karenitecin 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Factors Affecting Sales of Karenitecin 17
5.4.1 Good Safety Profile 17
5.4.2 Large Unmet Need 17
5.4.3 Low Efficacy 17
5.5 Drug Evaluation 18
5.5.1 Drug Risk Benefit Score 18
5.5.2 Intensity of Competition 19
5.6 Sales Forecasts 19
5.6.1 Target Patient Pool of Karenitecin 19
5.6.2 Dosing 20
5.6.3 Market Penetration 20
5.6.4 Annual Cost of Therapy 21
5.7 Sales Projections of Karenitecin 22
6 Ovarian Cancer Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abberiviations 31
6.3 Research Methodology 31
6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 32
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 33
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 34
6.3.8 Primary Research 34
6.3.9 Expert Panels 34
6.4 Contact Us 34
6.5 Disclaimer 35
6.6 Sources 35
List of Tables
Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Table 3: Detailed TNM Classification 14
Table 4: Drug Risk Benefit Score 18
Table 5: Karenitecin, Ovarian Cancer, Global, Sales Forecasts ($m), 20142020 22
Table 6: Karenitecin, Ovarian Cancer, The US, Sales Forecasts ($m), 20142020 23
Table 7: Karenitecin, Ovarian Cancer, The UK, Sales Forecasts ($m), 20142020 24
Table 8: Karenitecin, Ovarian Cancer, France, Sales Forecasts ($m), 20142020 25
Table 9: Karenitecin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20142020 26
Table 10: Karenitecin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20142020 27
Table 11: Karenitecin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20142020 28
Table 12: Karenitecin, Ovarian Cancer, Japan, Sales Forecasts ($m), 20142020 29
List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 10
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 11
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 11
Figure 6: Broad Classification of Ovarian Cancer 13
Figure 7: Classification of Ovarian Cancer 15
Figure 8: Drug Model Diagram of Karenitecin 20
Figure 9: Karenitecin, Ovarian Cancer, Global, Sales Forecasts ($m), 20142020 22
Figure 10: Karenitecin, Ovarian Cancer, The US, Sales Forecasts ($m), 20142020 23
Figure 11: Karenitecin, Ovarian Cancer, The UK, Sales Forecasts ($m), 20142020 24
Figure 12: Karenitecin, Ovarian Cancer, France, Sales Forecasts ($m), 20142020 25
Figure 13: Karenitecin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20142020 26
Figure 14: Karenitecin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20142020 27
Figure 15: Karenitecin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20142020 28
Figure 16: Karenitecin, Ovarian Cancer, Japan, Sales Forecasts ($m), 20142020 29
Figure 17: Karenitecin , Ovarian Cancer, Sales Distribution (%), By Country, 2020 30
Figure 18: Drug Model Diagram 33
Figure 19: Patients Approved for the Drug 33
Upcoming Reports:
|
Biopesticides Market - Global Industry Analysis, Market Size, Market Share And Forecasts, 2012 - 2018
By - Transparency Market Research
Biopesticides are essential for controlling the effect of agricultural pests, insects, and bacterial and fungal growth on food and field crops. Use of biopesticides can avoid the hazards caused by the use of chemical pesticides on the environment. Growing environmental concerns and stringent regulation from governments of many countries is opening up new growth opportunities for less toxic biopesticides.
Increasing health awareness is giving rise to the new trend of organic food consumption, thus boosting the demand for biopesticides. Moreover, increasing...
|
|
Graphene Market - Global Forecast, Trends, Industry Size, Market Share, Analysis And Forecast, 2012-2018
By - Transparency Market Research
Graphene, also known as “magic material” by various research labs, is composed of pure carbon placed in a hexagonal pattern. Graphene can be used in a variety of applications owing to its superior performance. The material is said to offer extraordinary properties in all its applications. Graphene is useful in high-end technologies like RFID, sensors and super capacitors among others.
Graphene can be manufacturer by various processes. The manufacturing of graphene is done by chemical vapor deposition, liquid phase exfoliation, plasma and reduced graphene...
|
|
Ethanolamines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Ethanolamines (ETA) are a group of compounds such as carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, and doxylamine that act both as primary amines as well as primary alcohols since they comprise of a hydroxyl group in their chemical structure. ETA are corrosive, colorless, flammable, viscous, and toxic liquids used in solutions and dispersions to scrub acids, as feedstock material in the manufacture of detergents, emulsification agents, varnishes & polishes, and as other chemical intermediaries.
China and United States are expected to lead the market...
|
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
Select License type:
Share this report
Latest Reports
- The Future of the Haircare Market in Egypt to 2017
- The Future of the Haircare Market in Denmark to 2017
- Overview of international chemical market
- Russian market of microcredits and lending to SME in Russia
- Overview of furniture market
- The Future of the Haircare Market in Czech Republic to 2017
- LTE Strategy 2013 - 2018
- Natural And Synthetic (Ethoxyquin, BHA, BHT) Animal Feed Antioxidants Market For Swine, Poultry, Cattle And Aquaculture - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
- Seed Treatment Market (Insecticides, Fungicides, Other Chemical And Nonchemical Treatment) For Corn, Soybean, Wheat, Canola, Cotton And Others - Global Industry Analysis, Size, Share, Growth And Forecast, 2012 - 2018
- Future of the Spanish Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2018
Related News
|
One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
|
|
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples.
The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
|
|
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
|
|
Battling against flu, vaccination necessary for health workers
Sep 14, 2012
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease.
Health officials...
|
|
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...
|
